Robbins LLP Is Investigating the Officers and Directors of Celgene Corporation (CELG) on Behalf of Shareholders
Robbins LLP is investigating whether certain officers and directors of Celgene Corporation (NasdaqGS: CELG) breached their fiduciary duties to shareholders. Celgene discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases.
Celgene Is Being Investigated for Marketing Cancer Therapies for Unapproved Uses
Since 2011, Celgene has been investigated by several United States Attorneys’ Offices, including the Central District of California, Northern District of Alabama, and the Eastern District of Texas, for aggressively marketing THALOMID and REVLIMID for unapproved uses. The investigations also include possible improper payments to physicians for prescribing the company’s top selling cancer drugs, as well as concerns that the company failed to fully disclose possible side effects and necessary warnings about using THALOMID and REVLIMID.
Celgene Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.